Recommendations for management of patients with neuroendocrine liver metastases

Working Group on Neuroendocrine Liver Metastases; Andrea Frilling; Irvin M Modlin; Mark Kidd; Christopher Russell; Stefan Breitenstein; Riad Salem; Dik Kwekkeboom; Wan-yee Lau; Catherine Klersy; Olivier Garden; Valerie Vilgrain; Brian Davidson; Mark Siegler; Martyn Caplin; Enrico Solcia; Richard Schilsky

doi:10.1016/S1470-2045(13)70362-0

Recommendations for management of patients with neuroendocrine liver metastases

Working Group on Neuroendocrine Liver Metastases, Andrea Frilling, Irvin M Modlin, Mark Kidd, Christopher Russell, Stefan Breitenstein, Riad Salem, Dik Kwekkeboom, Wan-yee Lau, Catherine Klersy, Olivier Garden (Member of Group Organisation), Valerie Vilgrain, Brian Davidson, Mark Siegler, Martyn Caplin, Enrico Solcia, Richard Schilsky

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.

Original language	English
Pages (from-to)	e8-21
Journal	The Lancet Oncology
Volume	15
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(13)70362-0
Publication status	Published - Jan 2014

Keywords / Materials (for Non-textual outputs)

Biopsy
Hepatectomy
Humans
Liver Neoplasms
Neoadjuvant Therapy
Neoplastic Cells, Circulating
Neuroendocrine Tumors

Access to Document

10.1016/S1470-2045(13)70362-0

Cite this

Working Group on Neuroendocrine Liver Metastases, Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W., Klersy, C., Garden, O., Vilgrain, V., Davidson, B., Siegler, M., Caplin, M., Solcia, E., & Schilsky, R. (2014). Recommendations for management of patients with neuroendocrine liver metastases. The Lancet Oncology, 15(1), e8-21. https://doi.org/10.1016/S1470-2045(13)70362-0

@article{ee9989dd34d04436ae47c683dae7522f,

title = "Recommendations for management of patients with neuroendocrine liver metastases",

abstract = "Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.",

keywords = "Biopsy, Hepatectomy, Humans, Liver Neoplasms, Neoadjuvant Therapy, Neoplastic Cells, Circulating, Neuroendocrine Tumors",

author = "{Working Group on Neuroendocrine Liver Metastases} and Andrea Frilling and Modlin, {Irvin M} and Mark Kidd and Christopher Russell and Stefan Breitenstein and Riad Salem and Dik Kwekkeboom and Wan-yee Lau and Catherine Klersy and Olivier Garden and Valerie Vilgrain and Brian Davidson and Mark Siegler and Martyn Caplin and Enrico Solcia and Richard Schilsky",

year = "2014",

month = jan,

doi = "10.1016/S1470-2045(13)70362-0",

language = "English",

volume = "15",

pages = "e8--21",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

Working Group on Neuroendocrine Liver Metastases, Frilling, A, Modlin, IM, Kidd, M, Russell, C, Breitenstein, S, Salem, R, Kwekkeboom, D, Lau, W, Klersy, C, Garden, O, Vilgrain, V, Davidson, B, Siegler, M, Caplin, M, Solcia, E & Schilsky, R 2014, 'Recommendations for management of patients with neuroendocrine liver metastases', The Lancet Oncology, vol. 15, no. 1, pp. e8-21. https://doi.org/10.1016/S1470-2045(13)70362-0

TY - JOUR

T1 - Recommendations for management of patients with neuroendocrine liver metastases

AU - Working Group on Neuroendocrine Liver Metastases

AU - Frilling, Andrea

AU - Modlin, Irvin M

AU - Kidd, Mark

AU - Russell, Christopher

AU - Breitenstein, Stefan

AU - Salem, Riad

AU - Kwekkeboom, Dik

AU - Lau, Wan-yee

AU - Klersy, Catherine

AU - Vilgrain, Valerie

AU - Davidson, Brian

AU - Siegler, Mark

AU - Caplin, Martyn

AU - Solcia, Enrico

AU - Schilsky, Richard

A2 - Garden, Olivier

PY - 2014/1

Y1 - 2014/1

N2 - Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.

AB - Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.

KW - Biopsy

KW - Hepatectomy

KW - Humans

KW - Liver Neoplasms

KW - Neoadjuvant Therapy

KW - Neoplastic Cells, Circulating

KW - Neuroendocrine Tumors

U2 - 10.1016/S1470-2045(13)70362-0

DO - 10.1016/S1470-2045(13)70362-0

M3 - Article

C2 - 24384494

SN - 1470-2045

VL - 15

SP - e8-21

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 1

ER -

Recommendations for management of patients with neuroendocrine liver metastases

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this